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1. Introduction
Human pluripotent stem cells (hPSC) include human embryonic stem cells (hESC) and hu‐
man induced pluripotent stem cells (hIPSC). Due to their inherent ability to self-renew in‐
definitely in vitro and to give rise to essentially all cell lineages, both cell types have
enormous potential for applications in regenerative medicine, but differ in their origin.
HESC are derived from early pre-implantation stage embryos and have the capacity, known
as pluripotency, to generate any other cell type of the human body. HESC can be differentiat‐
ed in the laboratory, a procedure aimed at the generation of healthy somatic cells that even‐
tually could be used in a large variety of applications including therapeutic options.
However, work with hESC raises ethical concerns regarding the use of human early pre-im‐
plantation embryos, as well as concerns regarding the future use of hESC-derived cells in
non-autologous cell transplantation therapies due to immune rejection of hESC-derived tis‐
sues, given that hESC are non-self. These concerns appeared to be overcome when it was
demonstrated that pluripotency could be induced in differentiated somatic (adult) cells of
the body by introduction of a cocktail of pluripotency-associated transcription factors, usu‐
ally OCT4, SOX2, KLF4 and c-MYC [1]. This process is known as reprogramming, and gener‐
ates human induced pluripotent stem cells (hIPSC), which show an embryonic-like state
similar to hESC (for review see [2]). Human iPSC are considered to have immense potential
for regenerative medicine, do not require the use of donated human embryos for their gen‐
eration and may provide an alternative and suitable resource for autologous cell-based
therapies, in which cells obtained from the patient could be used to generate self-hIPSC fol‐
lowed by differentiation to relevant lineages required for therapeutic intervention. Howev‐
er, disturbingly, mouse experiments have shown that autologous mouse iPSC can induce
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unexpected T-cell-dependent immune response in syngeneic recipients [3], suggesting that
hIPSC-derived cell types should also be evaluated for immunogenicity before any clinical
application.
Given that: (i) the generation of human iPSC does not require destruction of embryos, (ii)
that many iPSC lines can be established from a single patient, (iii) hIPSC are predicted to
lead to patient specific therapies and (iv) that hIPSC could be used as a source of somatic
cells for toxicology and drug screening studies, many research programs have shifted their
focus from solely hESC-based research to also include work on hIPSC. However, despite the
phenotypic similarities with hESC, recent reports described the worrying phenomena of ele‐
vated genetic [4-6] and epigenetic abnormalities [7-9] in hIPSC, raising concern about the
suitability of hiPSC-derived cell types for future clinical applications. Nevertheless, it ap‐
pears that these abnormalities are not present in all iPSC cell lines and that at least in mouse
studies the current reprogramming methods can produce pluripotent mouse IPSC lines that
lack identifiable genomic alterations [10], a result that calls for additional experiments to ex‐
plain the discrepancies with respect to hIPSC [4-6]. It is becoming increasingly obvious,
based on the studies described, that it is extremely important for hIPSC-derived therapies to
become a reality in the clinic, that researchers develop diagnostic tools to definitively recog‐
nise clinically “safe” and “unsafe” hIPSC lines. This is likely to be a complex and cumber‐
some task due to the large number of methodological approaches used. To date hIPSC lines
have been generated (for review see [2]); using a large number of different vectors to intro‐
duce the transgenes, with variations in the combinations of genes used to induce pluripoten‐
cy, with significant modifications in culture conditions aimed at improving reprogramming
efficiency, and from many of the more than 200 cell types in the human body. It will be a
challenging undertaking to develop individual safety profiles for the multitude of hIPSC
lines developed to date. Additionally, hIPSC-derived cells/tissues intended for clinical appli‐
cations will need to comply with the following conditions: (i) adequate numbers of cells for
transplantation therapy, (ii) hIPSC differentiated progeny need to be tolerated (not immu‐
norejected) by a patient’s immune system and (iii) hIPSC-derived cells should not generate
teratoma-like tumours at any time after transplantation. In vitro and pre-clinical optimisa‐
tions for these parameters are essential before hIPSC-derived technologies reach the clinic.
In this Chapter, we discuss the prospects for clinical applications using pluripotent cells, fo‐
cusing on an evaluation of hIPSC cell potential and on the development of methods for the
identification and removal of unwanted residual tumorigenic pluripotent cells from hIPSC-
derived cell populations following differentiation.
2. The risk of tumour formation from residual pluripotent cells
In vivo, pluripotent stem cells reside only during a short time in embryonic development.
Conversely, in vitro, hESC and hIPSC lines can be propagated indefinitely in the embryonic-
like state and remain pluripotent, or with the appropriate cues they can give rise to a range
of body cell types. For human cells, the most accepted in vivo assay to prove pluripotency is
Pluripotent Stem Cells556
the generation of teratomas in immuno-deficient mice (ie: NOD-SCID and NOD/SCID
IL2Rγ-/- mice), by injection of putative pluripotent hPSC into organs like testis, kidney or
muscle. Teratomas are benign solid tumours that contain a mixture of differentiated tissues
such as nerve cells, muscle cells or cartilage. If a human cell line generates teratomas, it is
considered pluripotent, because teratomas emulate differentiation in the developing em‐
bryo, albeit in a disorganised fashion, by generation of tissues resembling different parts of
the embryo known as embryonic germ layers (i.e.: Ectoderm, Mesoderm and Endoderm).
In the clinical context, pluripotent stem cells will not be transplanted, rather the progenitors
and/or specialised somatic cell types that are derived from hPSC will be used. It is the hope
of researchers working in the expanding field of regenerative medicine that hPSC-derived
cell populations will integrate into tissues and receive appropriate cues to functionally cor‐
rect diseased or injured tissue, (i.e.: Parkinson's disease, Huntington's disease, cardiac fail‐
ure, multiple sclerosis or macular degeneration). Therefore, differentiated somatic cell types
are the final product for transplantation and therapeutic applications, and pluripotent stem
cells are the stable source to generate those somatic cells or their progenitors (depending
upon disease context) in the laboratory. In this context, the presence of even low frequency
residual undifferentiated stem cells capable of teratoma formation becomes a highly unde‐
sirable feature when considering hPSC-derived somatic cells for transplantation into pa‐
tients. Differentiated cells will not be deemed safe for use in regenerative medicine if they
generate tumours at any time after transplantation. To comply with this requirement, we
consider that researchers should aim at the generation of pluripotent stem cell-free samples.
Therefore, it will be essential to be able to monitor if any undifferentiated pluripotent cells
remain after differentiation protocols, and if so, remove them without damaging the poten‐
tially therapeutic differentiated cells. Evidence supporting this statement is that it is known
that the numbers of pluripotent cells injected experimentally have a directly proportional ef‐
fect on how fast the teratomas develop and the size of the tumour [11-13]. It has also been
reported that at doses of 1,000 pluripotent cells, teratomas developed with 40% efficiency
but with 10,000 cells the efficiency increased to 100% [12]. However, as few as two pluripo‐
tent cells have been reported to induce teratoma formation in immuno-deficient mice, al‐
though with lower efficiency [11]. Taken together, this might mean that one remaining
pluripotent stem cell in a patient bound cell preparation could lead to teratoma formation.
There is some limited evidence that potentially refutes the tumorgenic potential of low
doses of pluripotent cells. This evidence is demonstrated by experiments showing that two
pluripotent cells transplanted into syngeneic immunocompetent mice practically abolished
tumour formation [11], most likely because those stem cells were cleared by the immune
system. This could be taken to imply that in the clinical context of immuno-competent pa‐
tients, low contamination with human pluripotent stem cells may be safe, but nevertheless
for hPSC-derived cell populations to be approved for use in clinical trials their stringent
elimination will be a requirement. Furthermore, the site of transplantation needs to be taken
into account as not all places in the body are equally permissive for teratoma growth and
development and contaminating hPSC may also migrate to alternative and possibly more
permissive sites for teratoma growth post transplantation. For instance, it has been reported
that similar number of pluripotent stem cells injected into immuno-deprived mice induced
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teratomas with 12.5% efficiency in intramuscular injections, 33% in subcutaneous injections,
60% in intratesticular, and approximately 100% under the kidney capsule [14]. Although
many variables can potentially affect teratoma formation, we consider that the most ethical
and safest cell population for transplantation into patients should be classified as pluripo‐
tent stem cell-free.
3. How to purge residual tumorigenic pluripotent stem cells from
differentiated cell types?
To  guarantee  that  no  undifferentiated  pluripotent  stem  cells  are  present  in  a  hESC  or
hiPSC-differentiated progeny intended for transplantation into patients,  researchers need
assays to detect those residual pluripotent cells and efficient methods to purge stem cells
from the differentiated cell populations. A good strategy to detect pluripotent cells is us‐
ing antibodies that detect surface markers on live hPSC that are not present on differen‐
tiated  cell  types.  After  antibody-mediated  detection  of  stem  cells,  other  technologies
could be coupled to  the antibodies  in  order  to  eliminate  residual  pluripotent  stem cells
from  the  transplantation  sample.  For  instance,  Fluorescent  or  Magnetic  Activated  Cell
Sorting (FACS and MACS) could be used with antibody detection for elimination of the
targeted cells.
There are only a few available antibodies that detect cell surface markers on live human
pluripotent  stem cells  (See  table  1).  Researchers,  utilising  the  available  antibodies,  have
described methods to eliminate residual  pluripotent  cells  from samples of  differentiated
cell types. For instance the SSEA-4 antibody first demonstrated its utility in purging plu‐
ripotent stem cells from simian ESC-derived hematopoietic precursors used for transplan‐
tations  into  monkeys  [15].  In  this  study,  researchers  used  SSEA-4  antibody  to  detect
residual  pluripotent  cells  that  persisted  despite  rigorous  and  extended  differentiation
protocols  for  hematopoietic  precursors.  SSEA-4  negative  cells  obtained  by  fluorescence
activated cell sorting (FACS) did not develop teratomas, whereas teratomas were consis‐
tently  observed  in  hematopoietic  precursors  showing  presence  of  SSEA-4  positive  cells
[15]. The SSEA-4 and Tra-1-60 antibodies have also been compared for their efficiency in
detecting  and  removing  residual  hPSC,  by  FACS  or  magnetic-activated  cell  sorting
MACS [16].  This comparison revealed that MACS technology was not efficient for com‐
plete  depletion  of  hESCs,  with  an  average  of  82% retention  of  hESCs,  and  highlighted
that  negative  selection via  FACS may be  a  preferred approach to  eliminate  undesirable
hESCs from differentiated populations  [16].  However,  a  note  of  caution against  the  use
of  single  antibodies  to  detect  hESCs  emerged  from  data  showing  that  47%  of  SSEA-4
low-expressing hESCs exhibited a  high level  of  expression for  TRA-1-60.  Therefore,  de‐
tection of  a  single  cell-surface  marker  may not  be  sufficient  to  eliminate  all  pluripotent
stem  cells,  and  methods  that  use  multiple  antibodies  detecting  different  epitopes  ex‐
pressed by hESCs are more likely to be successful [16].
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Antibody Isotype Cell-surface antigen Source/Supplier Literature reference
GCTM-2 IgM Keratan sulphate proteogly‐can (KSPG)-protein core
Kindly donated by Prof. Mar‐
tin Pera
Laslett et al., 2003 [27];
Pera et al.,2003 [28].
mAB 84 IgM Podocalyxin (PODXL); CD34family member.
Millipore MAB4414 http://
www.millipore.com Choo et al., 2008 [17].
PHM-5 IgG1 Podocalyxin (PODXL); CD34family member.
Millipore MAB430 http://
www.millipore.com
Kerjaschki et al., 1986
[29].
SSEA-3 IgM Globoseries glycolipid Millipore MAB4303 http://www.millipore.com Kannagi et al., 1983 [30].
SSEA-4 IgG3 Globoseries glycolipid Millipore MAB4304 http://www.millipore.com Kannagi et al., 1983 [31].
TG30 (CD9) IgG2a 25kDa tetraspannin proteinCD9
Millipore MAB4427 http://
www.millipore.com
Laslett et al., 2003 [27];
Pera et al., 2003 [28].
TG343 IgM
KSPG-protein core (detects
the same antigen as the
GCTM-2 antibody).
Millipore MAB4346 http://
www.millipore.com Cooper et al., 2002 [32].
TRA-1-60 IgM KSPG-carbohydrate side chain Millipore MAB4360 http://www.millipore.com Andrews et al., 1984 [33].
TRA-1-81 IgM KSPG-carbohydrate side chain Millipore MAB4381 http://www.millipore.com Andrews et al., 1984 [33].
Table 1. Antibodies that are reactive with cell surface markers expressed on human pluripotent stem cells
The studies described above point to FACS technology coupled to antibody detection of sur‐
face markers as a good strategy to eliminate residual undifferentiated pluripotent cells and
recover differentiated live cells for further applications such as re-culture or transplantation.
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However, as the viability of hPSC-derived lineage progenitors or more mature cell types can
be compromised post-FACS, caused by shearing forces, laser damage or osmotic stress, oth‐
er technologies such as MACS may be better suited in these instances. Although MACS does
not completely remove all hESCs in a single pass [16], this technology exhibits higher cell
viability than FACS and it is possible that subsequent positive selections by MACS using
multiple antibodies for different hESC cell surface markers could completely remove all
hESCs. An alternative approach to MACS could be to use cytotoxic antibodies directed
against hESC surface antigens or chemicals that could selectively eliminate hESCs without
affecting their derivatives. An example of a cytotoxic antibody that detects and removes
hESCs is the monoclonal antibody mAB-84 [17], which binds to PODXL (Podocalyxin-like
protein 1) on hESCs and initiates a sequence of events that leads to hESC-membrane dam‐
age by formation of leaking pores [18]. It has been proposed that using the monoclonal anti‐
body mAB-84 in a two-step cell-cell separation approach can eliminate teratoma-forming
hESC from differentiated cell types [19]. In this strategy, an initial depletion of hESCs was
achieved via MACS using a panel of commonly used hESC cell-surface markers, which was
followed by selective elimination of residual undifferentiated stem cells post-MACS using
the cytotoxic antibody mAB-84, an approach that appears to increase the safety of cell trans‐
plantation [19].
Selective elimination of residual human pluripotent stem cells after differentiation can al‐
so  be  achieved  by  targeting  apoptosis-meditating  receptors  that  are  differentially  ex‐
pressed  in  undifferentiated  stem  cells  and  absent  in  hESC  derivatives.  Therefore,
stimulation of these specific hESC apoptotic receptors induce programmed cell death on‐
ly in the residual stem cells without affecting their differentiated progeny. One example
of this kind of receptor is the prostate apoptosis response-4 (PAR-4), which mediates ce‐
ramide  or  ceramide-analogue-induced  apoptosis  in  proliferating  stem  cells  [20].  The
apoptotic response appears to be specific for PAR-4(+) stem cells, and given that ESC-dif‐
ferentiated progenies  such as  neuro-progenitors  express  very  low levels  of  PAR-4,  they
are  less  sensitive  to  ceramide  induced  apoptosis  [20].  Using  this  approach,  ceramide
treatment appears to prevent teratoma formation when transplanting neural  progenitors
derived from ES cells [20] although it is likely that regulatory assays will require a more
stringent method. Although PAR-4 induced apoptosis by ceramides appears an effective
way to  eliminate  residual  pluripotent  stem cells  following differentiation,  this  approach
has not been broadly tested.
4. Antibodies against cell surface markers
of human stem cells
The  scarcity  of  antibodies  directed  against  cell  surface  markers  that  recognize  live  hu‐
man pluripotent stem cells (See table 1) is compounded by the fact that most of these an‐
tibodies  lack  identification  of  their  encoding  gene.  Indeed,  some cell  surface  antibodies
do  not  recognize  proteins,  but  complex  carbohydrate  and  lipid  moieties  for  which  the
corresponding gene is not yet identified. Despite this,  these complex moieties are strong
Pluripotent Stem Cells560
antigens  that  elicit  highly  sensitive  antibodies  that  recognize  human  pluripotent  stem
cells.  Furthermore,  a  caveat  is  that  stem-cell  antibodies  could  also  be  immunoreactive
with  some  embryonic  tissues,  or  some  mature  cell  types,  becoming  problematic  with
some hESC differentiation protocols.  Therefore,  depending on the phenotype of  the tar‐
get  somatic  cells,  selected  antibodies  used  to  detect  human pluripotent  cells  should  be
selected  that  do  not  react  with  the  differentiated  cells  intended for  transplantation.  For
instance,  if  working with  hESC-derived renal  tissues  for  treatment  of  kidney disorders,
PODXL  antibodies  should  not  be  used  alone  to  detect  stem  cells  because  Podocalyxin
protein is also expressed in glomerular podocytes.
The information in the previous section demonstrates that FACS and MACS technologies
are  potential  methods for  the elimination of  residual  pluripotent  cells  following in  vitro
differentiation (Figure 1).  Both methodological approaches use cell surface antibodies for
the labelling and detection of  undifferentiated live hPSC. The advantage of  live cell  de‐
tection using either FACS or MACS is the ability to retrieve live hESC or hIPSC-deriva‐
tives  that  could  be  used  for  in  vitro  re-culture  and  expansion,  or,  ultimately,
transplantation. However, FACS and MACS studies have also revealed the immunologi‐
cal complexity of in-vitro  hESC cultures. HESC cultures contain a continuum of different
subpopulations,  where  some  hESC  subpopulations  express  low  levels  of  one  surface
marker  and  at  the  same  time  high  levels  of  another  [16,  21-23].  These  findings  imply
strongly  that  a  single  cell-surface  marker  is  not  sufficient  to  eliminate  all  pluripotent
stem cells [16, 21-23]. Therefore, any attempt to eliminate all hESC pluripotent subpopu‐
lations should rely on methods that  use multiple antibodies detecting different epitopes
expressed by hESCs. For instance, SSEA-4-coupled MACS showed an average 82% reten‐
tion of hESCs [16], but when a panel of cell surface antibodies directed to different epito‐
pes  was  used  with  MACS,  the  removal  of  undifferentiated  hESCs  raised  to  98%  on
average [19].
In  our  laboratory,  we  have  been  working  on  the  development  of  monoclonal  antibody
panels  against  extracellular  markers  that  allow  efficient  human  pluripotent  cell  separa‐
tion from mixed populations of cultured cells, an essential requirement for safe hESC or
hIPSC-based therapeutics [21-24]. Towards this end, we have reported a FACS-based im‐
muno-transcriptional profiling system based on the detection of two pluripotency-associ‐
ated  cell  surface  antigens  TG30  (CD9)  and  GCTM-2,  [25-26].  This  method  is  useful  to
characterise  multiple  human pluripotent  stem cell  lines,  and to  identify  the  subpopula‐
tions  that  are  found  in  hESC  in-vitro  continuous  culture  [21-22].  Ongoing  unpublished
observations indicate that this double staining of human stem cells using two cell-surface
markers is a better way to eliminate residual and persistent undifferentiated pluripotent
cells  using FACS in  both hESC and hIPSC lines.  Nevertheless,  we are  aware that  there
will  be differentiation contexts  in which TG30 (CD9) and GCTM-2 might  not  be appro‐
priate or sufficient to purge pluripotent cells from particular differentiated hPSC-deriva‐
tives.  Therefore  there  is  a  real  need  for  new  monoclonal  antibodies  that  detect  cell
surface proteins on live hPSC.
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Figure 1. Potential approaches to eliminate residual pluripotent stem cells after in vitro differentiation. Shown
are two potential methods that could be used to purge residual tumorigenic pluripotent stem cells from differentiat‐
ed cell types. (A): Human pluripotent stem cells (hPSC) are able to self-renew indefinitely in vitro. (B): These pluripotent
cells can be induced to differentiate in vitro to generate healthy progenitors and/or specialised somatic cell types that
could potentially be used for transplantation and therapeutic applications. However, it is essential to monitor if any
residual undifferentiated pluripotent cells remain after differentiation protocols. If undifferentiated stem cells remain,
these cells should be removed without damaging the potentially therapeutic differentiated cells. Two good strategies
for elimination of residual pluripotent cells are Magnetic Activated Cell Sorting (C: MACS) and Fluorescence Activated
Cell Sorting (D: FACS). Both technologies are coupled to antibody detection of cell surface markers and allow retrieval
of live hPSC-derivatives that could be used for further in vitro re-culture and expansion, or in due course transplanta‐
tion (E).
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5. Conclusions
Human pluripotent  stem cells,  namely hESC and hIPSC lines,  may be the future  main‐
stay of medicine, providing a plethora of medical applications and transplantation thera‐
pies aimed at the correction of an important number of pathological disorders. However,
reaching clinical  applications based on hPSC-therapies has not been as fast  as expected.
The ability to generate hIPSC lines from a variety of tissue sources has brought hIPSC re‐
search  clearly  into  the  spotlight,  but  reports  on  their  epigenetic  instability  and  genetic
variability suggest that these cells are not yet clinic-ready. In addition, the concern of tu‐
morigenesis or teratoma formation is an unsolved problem for both hESC and hIPSC re‐
search.  If  differentiation  protocols  are  not  100%  efficient  and  yield  a  mixture  of
differentiated and undifferentiated cells,  this  presents  a  significant  risk  of  teratoma for‐
mation after transplantation. It is clear that adequate safety assays for hESC or hIPSC-de‐
rived technologies  are  of  the  utmost  importance  to  aid  in  the  safe  translation from the
bench to the clinic. This includes the essential monitoring of any residual undifferentiated
pluripotent  cells  after  differentiation  protocols,  an  unavoidable  methodological  step  in
any sample to be used in the clinic. A variety of approaches have been discussed in this
chapter to help to eliminate the undesirable residual pluripotent stem cells from samples
intended for transplantation. However, there is an ongoing need to improve these separa‐
tion methods in order to achieve hPSC free samples in a rapid, easy, safe, cost effective,
scalable and clinically applicable way. We expect that novel cell-surface antibodies recog‐
nizing live pluripotent stem cells will strongly contribute to this ongoing search.
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